SG Americas Securities LLC Has $291,000 Stake in Medpace Holdings, Inc. $MEDP

SG Americas Securities LLC decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 71.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 928 shares of the company’s stock after selling 2,373 shares during the quarter. SG Americas Securities LLC’s holdings in Medpace were worth $291,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Assetmark Inc. increased its stake in Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after acquiring an additional 43 shares during the period. HB Wealth Management LLC acquired a new stake in shares of Medpace during the 1st quarter worth approximately $256,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Medpace by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,046 shares of the company’s stock valued at $2,147,000 after purchasing an additional 326 shares during the period. LPL Financial LLC raised its stake in shares of Medpace by 2.3% in the first quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock valued at $5,469,000 after purchasing an additional 414 shares in the last quarter. Finally, Meeder Advisory Services Inc. raised its stake in shares of Medpace by 22.2% in the first quarter. Meeder Advisory Services Inc. now owns 843 shares of the company’s stock valued at $257,000 after purchasing an additional 153 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.2%

Shares of MEDP stock opened at $599.50 on Friday. The company has a market capitalization of $16.89 billion, a P/E ratio of 41.92, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The firm has a 50-day moving average price of $560.60 and a 200 day moving average price of $444.37.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the firm earned $3.01 earnings per share. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MEDP shares. Mizuho boosted their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a report on Friday, October 24th. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. BMO Capital Markets began coverage on shares of Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $487.18.

Insiders Place Their Bets

In other Medpace news, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction on Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 42,392 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $615.52, for a total value of $26,093,123.84. Following the completion of the transaction, the chief executive officer directly owned 732,210 shares in the company, valued at approximately $450,689,899.20. This represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 317,597 shares of company stock valued at $189,967,248. Company insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.